cancer-immunotherapy

Documents about cancer-immunotherapy

• Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)#245583ClinicalTrials.gov
• High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma#369837ClinicalTrials.gov
• Current Status of Immunotherapy in Resectable Lung Cancer.#433898NCBI PubMed Central
• Functional Characterization of Potential New Agents for Cancer Immunotherapy#643930Harvard DASH
• Neoadjuvant Imiquimod Immunotherapy for Oral Cancer#651235ClinicalTrials.gov
• Targeting splicing-derived neoantigens for precision cancer immunotherapy.#685587NCBI PubMed Central
• Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy#841103ClinicalTrials.gov
• Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer#471443ClinicalTrials.gov
• Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study#143577ClinicalTrials.gov
• TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer#238096ClinicalTrials.gov
• Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer#245516ClinicalTrials.gov
• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer#373617ClinicalTrials.gov
• EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER#407717ClinicalTrials.gov
• Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer#471448ClinicalTrials.gov
• Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer#848490ClinicalTrials.gov
• Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer#858739ClinicalTrials.gov
• Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.#405169ClinicalTrials.gov
• Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?#834389ClinicalTrials.gov
• Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer#136339ClinicalTrials.gov
• LIFE - Lung Cancer, Immunotherapy, Frailty, Effect#146440ClinicalTrials.gov
• Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients#162472ClinicalTrials.gov
• Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.#174857ClinicalTrials.gov
• Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma#217028ClinicalTrials.gov
• Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer#226251ClinicalTrials.gov
• Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma#256892ClinicalTrials.gov
• Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy#261520ClinicalTrials.gov
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC#314317ClinicalTrials.gov
• FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer#321682ClinicalTrials.gov
• Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer#346921ClinicalTrials.gov
• TF2- Small Cell Lung Cancer Radio Immunotherapy#353280ClinicalTrials.gov
• Colorectal Cancer, Liver Metastases and Biotherapies#364055HAL (France)
• Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer#377406ClinicalTrials.gov
• Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential#869221ClinicalTrials.gov
• Table 1_Global research trends and emerging frontiers of intratumoral microbiota in cancer immunotherapy: a bibliometric and visualization analysis.docx#384349Figshare
• Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer#158236ClinicalTrials.gov
• Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer#217023ClinicalTrials.gov
• VSV-02 Compassionate Use in Advanced Solid Tumors#230415ClinicalTrials.gov
• Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer#448273ClinicalTrials.gov
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial#140997ClinicalTrials.gov
• Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC#325314ClinicalTrials.gov
• Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells#460083ClinicalTrials.gov
• "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"#471446ClinicalTrials.gov
• Improving the Use of Immunotherapy to Treat Liver Cancer#471451ClinicalTrials.gov
• Equity in Neurotoxicity Care in the Era of Cancer Immunotherapy.#645521NCBI PubMed Central
• FMT to Convert Response to Immunotherapy#668831ClinicalTrials.gov
• A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer#307455ClinicalTrials.gov
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers#121340ClinicalTrials.gov
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy#332762ClinicalTrials.gov
• Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial#417553ClinicalTrials.gov
• Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases#852021ClinicalTrials.gov